Related Experiment Video
Updated: Aug 14, 2026
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Cytotoxic Action of Palladium-Based Compound on Prostate Stem Cells, Primary Prostate Epithelial Cells, Prostate
Long Cheng1, Yan Wang2, Jiawei Wang1
1Department of Urology, The Second People's Hospital of Wuhu, Wuhu, Anhui Province, China.
Objective:
Prostate cancer is one of the most common types of cancer found to occur in males and is ranked as the second-highest cause of cancer-associated deaths among male patients. In this study, we have shown the influence of a new palladium-based anticancer agent in contrast to the six distinct prostate cancer lines and the primary cultures.
Methods:
In this study, we have used six distinct prostate cell lines, that is, PNT2-C2, LNCaP, BPH-1, PC-3, PNT1A, and P4E6. The MTP and ATP assay were performed to evaluate the growth of the cell and the flow cytometry to investigate the status of the cell cycle. The antigrowth effect of the palladium complex was evaluated against different cell lines at three time zones 24 h, 48 h, and 72 h. [PdCl(terpy)] (capsule)-2H2O is synthesized by direct encapsulation of equimolar amounts of capsule ions into [Pd (terpy) Cl] Cl-2H2O.
Results:
A comparative analysis was done on 25 mM etoposide and 12 mM cisplatin, cytotoxic agents. The lowest IC50 value at 72 hours was 0.128 mM for BPH-1 cell lines with 0.139 mM, whereas PNT2-C2 cells were found to be most resistant with IC50 values of 0.829 mM. The antigrowth effect of palladium complex on cell lines was measured using the MTS assay at 24, 48, and 72 hours. BPH-1, PNT2-C2, and PNT1A either possess normal tissues or have benign prostatic hyperplasia tissues whereas P4E6, PC-3, and LNCaP cell lines possess malignant origin. The Pd complex exhibited significant cytotoxic action in stem cells when compared against etoposide. An antigrowth effect was reported for Pd complex at lower concentration, but it was more cytotoxic than etoposide with significant cytotoxicity (P=0.001).
Conclusion:
The palladium complex experienced a substantial antigrowth influence over most of the prostate tumor cell lines and the primary cultures, eventually, leading to the implementation of this Pd complex in the treating procedure of metastatic prostate cancer, which is tremendously resistant to the traditional treatment.
Insights
A novel palladium complex demonstrates significant anti-growth effects on prostate cancer cell lines. This new agent shows promise as a potent treatment for metastatic prostate cancer, outperforming traditional therapies.
Area of Science:
- Oncology
- Medicinal Chemistry
- Cancer Biology
Background:
- Prostate cancer is a leading cause of cancer-related deaths in males.
- Existing treatments for metastatic prostate cancer often face resistance.
Purpose of the Study:
- To evaluate the anti-cancer efficacy of a new palladium-based compound.
- To compare its effects against established chemotherapeutic agents.
Main Methods:
- Utilized six distinct prostate cell lines (PNT2-C2, LNCaP, BPH-1, PC-3, PNT1A, P4E6).
- Assessed cell viability and cell cycle progression using MTS, ATP assays, and flow cytometry.
- Evaluated the palladium complex's anti-growth effect at 24, 48, and 72 hours.
Main Results:
- The palladium complex exhibited significant cytotoxic and anti-growth effects across various prostate cancer cell lines.
- Demonstrated superior cytotoxicity compared to etoposide, particularly in stem cells.
- Achieved low IC50 values, indicating high potency against sensitive cell lines like BPH-1.
Conclusions:
- The palladium complex shows substantial anti-growth influence on prostate tumor cell lines and primary cultures.
- This agent holds potential for treating metastatic prostate cancer resistant to conventional therapies.
